▲ Peaking
Business
Vera kidney drug Trutakna shows strong final results in Phase 3 trial
Vera’s Trutakna slashes IgA nephropathy progression risk by 76%, reviving investor confidence and edging toward approval.
Iga Nephropathy
3 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Iga Nephropathy
This hub groups 3 separate news trends connected to Iga Nephropathy, spanning July 7, 2026 through September 16, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 26 article observations and 26 source signals, led by Business coverage. Use it to compare how individual events emerged, spread and changed over time.
◼ Archived
Business
🔮 fades ✓
Deerfield-backed Boulevard Bio embarks on ‘beautiful path to a cure’ with trio of immunology drugs
Boulevard Bio debuts with $65 million in funding to advance a pipeline of targeted antibody therapies focused on autoimmune disease.
◼ Archived
Business
🔮 fades ✗
FDA approves Vera Therapeutics kidney disease treatment
The FDA has approved Vera Therapeutics' dual-target drug, Trutakna, for the treatment of primary IgA nephropathy.